MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- AUROBINDO PHARMA - LUPIN
AUROBINDO PHARMA vs LUPIN - Comparison Results
AUROBINDO PHARMA Change
Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
LUPIN 
Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More
Current Valuations
| AUROBINDO PHARMA | LUPIN | AUROBINDO PHARMA/ LUPIN |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 16.0 | -128.4 | - | View Chart |
| P/BV | x | 3.3 | 2.9 | 114.0% | View Chart |
| Dividend Yield | % | 0.3 | 0.0 | - |
Financials
 AUROBINDO PHARMA  LUPIN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| AUROBINDO PHARMA Mar-19 |
LUPIN Mar-19 |
AUROBINDO PHARMA/ LUPIN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 830 | 986 | 84.2% | |
| Low | Rs | 527 | 720 | 73.2% | |
| Sales per share (Unadj.) | Rs | 333.9 | 369.5 | 90.4% | |
| Earnings per share (Unadj.) | Rs | 40.4 | 13.4 | 301.1% | |
| Cash flow per share (Unadj.) | Rs | 51.8 | 37.4 | 138.4% | |
| Dividends per share (Unadj.) | Rs | 2.50 | 0 | - | |
| Dividend yield (eoy) | % | 0.4 | 0 | - | |
| Book value per share (Unadj.) | Rs | 237.1 | 303.7 | 78.1% | |
| Shares outstanding (eoy) | m | 585.91 | 452.49 | 129.5% | |
| Bonus/Rights/Conversions | ESOP | ESOP | - | ||
| Price / Sales ratio | x | 2.0 | 2.3 | 88.0% | |
| Avg P/E ratio | x | 16.8 | 63.6 | 26.4% | |
| P/CF ratio (eoy) | x | 13.1 | 22.8 | 57.4% | |
| Price / Book Value ratio | x | 2.9 | 2.8 | 101.9% | |
| Dividend payout | % | 6.2 | 0 | - | |
| Avg Mkt Cap | Rs m | 397,569 | 386,064 | 103.0% | |
| No. of employees | `000 | 17.9 | 17.7 | 101.0% | |
| Total wages/salary | Rs m | 25,849 | 31,513 | 82.0% | |
| Avg. sales/employee | Rs Th | 10,956.9 | 9,453.8 | 115.9% | |
| Avg. wages/employee | Rs Th | 1,447.7 | 1,782.0 | 81.2% | |
| Avg. net profit/employee | Rs Th | 1,324.3 | 343.0 | 386.1% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 195,636 | 167,182 | 117.0% | |
| Other income | Rs m | 1,553 | 3,640 | 42.7% | |
| Total revenues | Rs m | 197,189 | 170,822 | 115.4% | |
| Gross profit | Rs m | 39,519 | 28,822 | 137.1% | |
| Depreciation | Rs m | 6,680 | 10,850 | 61.6% | |
| Interest | Rs m | 2,626 | 3,078 | 85.3% | |
| Profit before tax | Rs m | 31,767 | 18,534 | 171.4% | |
| Minority Interest | Rs m | 27 | -89 | -30.2% | |
| Prior Period Items | Rs m | 0 | 38 | 0.0% | |
| Extraordinary Inc (Exp) | Rs m | -881 | -3,400 | 25.9% | |
| Tax | Rs m | 7,269 | 9,017 | 80.6% | |
| Profit after tax | Rs m | 23,645 | 6,066 | 389.8% | |
| Gross profit margin | % | 20.2 | 17.2 | 117.2% | |
| Effective tax rate | % | 22.9 | 48.7 | 47.0% | |
| Net profit margin | % | 12.1 | 3.6 | 333.1% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 153,645 | 138,536 | 110.9% | |
| Current liabilities | Rs m | 120,429 | 61,299 | 196.5% | |
| Net working cap to sales | % | 17.0 | 46.2 | 36.8% | |
| Current ratio | x | 1.3 | 2.3 | 56.5% | |
| Inventory Days | Days | 135 | 84 | 161.4% | |
| Debtors Days | Days | 64 | 112 | 56.6% | |
| Net fixed assets | Rs m | 103,909 | 127,516 | 81.5% | |
| Share capital | Rs m | 586 | 905 | 64.7% | |
| "Free" reserves | Rs m | 138,322 | 136,517 | 101.3% | |
| Net worth | Rs m | 138,908 | 137,422 | 101.1% | |
| Long term debt | Rs m | 1,800 | 66,417 | 2.7% | |
| Total assets | Rs m | 264,544 | 279,494 | 94.7% | |
| Interest coverage | x | 13.1 | 7.0 | 186.5% | |
| Debt to equity ratio | x | 0 | 0.5 | 2.7% | |
| Sales to assets ratio | x | 0.7 | 0.6 | 123.6% | |
| Return on assets | % | 9.9 | 3.3 | 303.5% | |
| Return on equity | % | 17.0 | 4.4 | 385.7% | |
| Return on capital | % | 23.8 | 8.9 | 267.5% | |
| Exports to sales | % | 49.6 | 0 | - | |
| Imports to sales | % | 18.8 | 0 | - | |
| Exports (fob) | Rs m | 97,091 | NA | - | |
| Imports (cif) | Rs m | 36,741 | NA | - | |
| Fx inflow | Rs m | 97,316 | 59,414 | 163.8% | |
| Fx outflow | Rs m | 40,589 | 22,282 | 182.2% | |
| Net fx | Rs m | 56,727 | 37,132 | 152.8% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 16,220 | 16,660 | 97.4% | |
| From Investments | Rs m | -28,768 | -32,825 | 87.6% | |
| From Financial Activity | Rs m | 19,191 | 7,441 | 257.9% | |
| Net Cashflow | Rs m | 6,656 | -8,724 | -76.3% | |
Share Holding
| Indian Promoters | % | 54.1 | 46.6 | 116.1% | |
| Foreign collaborators | % | 0.0 | 0.2 | - | |
| Indian inst/Mut Fund | % | 8.0 | 11.3 | 70.4% | |
| FIIs | % | 27.7 | 31.9 | 86.8% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 10.2 | 10.1 | 101.0% | |
| Shareholders | 69,601 | 98,259 | 70.8% | ||
| Pledged promoter(s) holding | % | 8.6 | 0.0 | - |
Compare AUROBINDO PHARMA With: AJANTA PHARMA GLENMARK PHARMA SUN PHARMA STRIDES PHARMA SCIENCE FDC LTD.
Compare AUROBINDO PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Today's Market
Indian Indices Continue Momentum; Sensex Ends 187 Points Higher(Closing)
Indian share markets end on a positive note with the Sensex up by 187 points, while the Nifty closed up by 36 points.
Related Views on News
AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)
Jun 5, 2020 | Updated on Jun 5, 2020For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
LUPIN Announces Quarterly Results (4QFY20); Net Profit Up 35.5% (Quarterly Result Update)
Jun 1, 2020 | Updated on Jun 1, 2020For the quarter ended March 2020, LUPIN has posted a net profit of Rs 4 bn (up 35.5% YoY). Sales on the other hand came in at Rs 38 bn (down 12.7% YoY). Read on for a complete analysis of LUPIN's quarterly results.
AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)
Feb 7, 2020 | Updated on Feb 7, 2020For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)
Nov 15, 2019 | Updated on Nov 15, 2019For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)
Nov 7, 2019 | Updated on Nov 7, 2019For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.
More Views on NewsMost Popular
How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)
Jul 2, 2020In the first of two videos, I'll show you how to identify the best stocks for intraday trading.
Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)
Jun 25, 2020The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.
Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)
Jul 2, 2020Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...
Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)
Jun 24, 2020Rahul is ready for a repeat of his famous 2008 Tata Motors call.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2020
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
AUROBINDO PHARMA SHARE PRICE
Jul 7, 2020 (Close)
TRACK AUROBINDO PHARMA
- Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AUROBINDO PHARMA
AUROBINDO PHARMA 5-YR ANALYSIS
COMPARE AUROBINDO PHARMA WITH
FEATURED VIDEOS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.